Retatrutide vs Tirzepatide

On raw weight loss, retatrutide's 28.7% at 12mg beats tirzepatide's 20-22.5% by a meaningful margin - roughly 6-8 percentage points. The trials were run separately, not head-to-head, so the true gap may be smaller. Retatrutide also showed osteoarthritis pain improvement that tirzepatide trials did not capture. But tirzepatide has years of real-world use and FDA approvals for obesity and OSA. Newer does not always mean better, but in this case the efficacy signal is strong.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Tirzepatide hits only the first two. Glucagon agonism sounds counterintuitive - glucagon raises blood sugar - but in combination with GLP-1 it increases energy expenditure and fat oxidation. That third lever is what pushes weight loss from 20% to nearly 29%. The tradeoff is a slightly more complex side effect profile including the new dysesthesia signal.

Yes, compounded tirzepatide is still legally available through 503B outsourcing facilities and some telehealth platforms, typically $249-699 per month. The FDA's shortage list removal in 2024 changed the legal landscape, but compounding continues under specific exemptions. Retail Zepbound runs around $1,086 per month without insurance. Pricing, legal status, and availability all shift frequently, so verify current rules with your pharmacy.

It matters if obstructive sleep apnea is part of your picture. Tirzepatide became the first drug ever approved for OSA in adults with obesity (December 2024), which means some insurance plans now cover it for that indication where they would not for pure obesity. If you snore heavily, wake unrefreshed, or have a known OSA diagnosis, the tirzepatide approval opens a coverage pathway retatrutide will not have for years.

Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. They differ in FDA approval status, efficacy data, and cost.

In clinical trials, Retatrutide showed greater average weight loss (28.7%) compared to Tirzepatide (22.5%). Individual results may vary.

Retatrutide typically costs $1,200 - $1,500/mo, while Tirzepatide costs $1,100 - $1,100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). Tirzepatide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.